

**Version of Claims with Markings to Show Changes**

123. (Amended) A method of treating [or preventing] a mammal afflicted with an autoimmune disease [in a mammal] comprising administering to the mammal a purified polypeptide having the amino acid sequence set forth in [SEQ ID NO:1,] SEQ ID NO:2, [SEQ ID NO:3,] SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides.

124. The method of claim 123 wherein the purified polypeptide consists entirely of L-amino acids.

125. The method of claim 123 wherein the purified polypeptide consists entirely of D-amino acids.

126. (Canceled)

127. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 2.

128. (Canceled)

129. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 4.

130. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 5.

131. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 6.

132. The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 7.

133. (Amended) A method of treating [or preventing] a mammal afflicted with an autoimmune disease [in a mammal] comprising

administering to the mammal a pharmaceutical composition consisting essentially of a purified polypeptide having the amino acid sequence set forth in [SEQ ID NO:1,] SEQ ID NO:2, [SEQ ID NO:3,] SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, and a pharmaceutically acceptable carrier.

134. (Amended) The method of claim [123 or] 133 wherein said autoimmune disease is a B cell mediated autoimmune disease, a T cell mediated autoimmune disease, a demyelinating disease, an inflammatory disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, [rheumatoid arthritis,] or systemic lupus erythematosus.

135. The method of Claim 134, wherein said autoimmune disease is a B cell mediated autoimmune disease.

136. The method of Claim 134, wherein said autoimmune disease is a T cell mediated autoimmune disease.

137. The method of Claim 134, wherein said autoimmune disease is a demyelinating disease.

138. The method of Claim 134, wherein said autoimmune disease is multiple sclerosis.

139. The method of Claim 134, wherein said autoimmune disease is an inflammatory disease.

140. The method of Claim 134, wherein said autoimmune disease is rheumatoid arthritis.

141. The method of Claim 134, wherein said autoimmune disease is osteoarthritis.

142. (Amended) A method of treating [or preventing] graft versus host disease (GVHD), host versus graft disease (HVGD) or delayed-type hypersensitivity (DTH) in a mammal comprising administering to the mammal a purified polypeptide having the amino acid sequence [SEQ ID NO:1,] SEQ ID NO:2, [SEQ ID NO:3,] SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides.

143. (Withdrawn)

---

C10  
144. (New) The method of Claim 123, wherein said autoimmune disease is a B cell mediated autoimmune disease, a T cell mediated autoimmune disease, a demyelinating disease, an inflammatory disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, or systemic lupus erythematosus.

145. (New) The method of Claim 144, wherein said autoimmune disease is a B cell mediated autoimmune disease.

146. (New) The method of Claim 144, wherein said autoimmune disease is a T cell mediated autoimmune disease.

147. (New) The method of Claim 144, wherein said autoimmune disease is a demyelinating disease.

148. (New) The method of Claim 144, wherein said autoimmune disease is multiple sclerosis.

149. (New) The method of Claim 144, wherein said autoimmune disease is an inflammatory disease.

150. (New) The method of Claim 144, wherein said autoimmune disease is rheumatoid arthritis.

151. (New) The method of Claim 144, wherein said autoimmune disease is osteoarthritis.

152. (New) A method of delaying the onset of an autoimmune disease in a mammal comprising administering to the mammal a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO:7, or a mixture of the purified polypeptides.

153. (New) The method of claim 152, wherein, the purified polypeptide consists entirely of L-amino acids.

154. (New) The method of claim 152, wherein the purified polypeptide consists entirely of D-amino acids.

155. (New) The method of claim 152, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 2.

156. (New) The method of claim 152, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 7.

157. (New) A method of delaying the onset of an autoimmune disease in a mammal comprising administering to the mammal a pharmaceutical composition consisting essentially of a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, and a pharmaceutically acceptable carrier.

Cont  
C6

158. (New) The method of claim 157, wherein said autoimmune disease is a B cell mediated autoimmune disease, a T cell mediated autoimmune disease, a demyelinating disease, an inflammatory disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune oophoritis, autoimmune thyroiditis, autoimmune uveoretinitis, Crohn's disease, chronic immune thrombocytopenic purpura, colitis, contact sensitivity disease, diabetes mellitus, Graves disease, Guillain-Barre's syndrome, Hashimoto's disease, idiopathic myxedema, myasthenia gravis, psoriasis, pemphigus vulgaris, or systemic lupus erythematosus.

159. (New) The method of Claim 158, wherein said autoimmune disease is a B cell mediated autoimmune disease.

160. (New) The method of Claim 158, wherein said autoimmune disease is a T cell mediated autoimmune disease.

C 16 cont  
161. (New) The method of Claim 158, wherein said autoimmune disease is a demyelinating disease.

162. (New) The method of Claim 158, wherein said autoimmune disease is multiple sclerosis.

163. (New) The method of Claim 158, wherein said autoimmune disease is an inflammatory disease.

164. (New) The method of Claim 158, wherein said autoimmune disease is rheumatoid arthritis.

165. (New) The method of Claim 158, wherein said autoimmune disease is osteoarthritis.

166. (New) A method of delaying the onset of graft versus host disease (GVHD), host versus graft disease (HVGD) or delayed-type hypersensitivity (DTH) in a mammal comprising administering to the mammal a purified polypeptide having the

C10 <sup>cont</sup>  
amino acid sequence SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ  
ID NO:6 or SEQ ID NO:7, or a mixture of the purified  
polypeptides.

---